Metis Partners was appointed by PCR LLP to sell the IP assets of Apta Biosciences.
Apta was a biotechnology developer of medical diagnostics and therapeutics, utilizing synesthetic molecules as an alternative to antibodies. APTA was a spin-out company building upon patented technology previously developed over a ten-year period by major Japanese technology company, Fujitsu.
IP Assets Sold
- Patent portfolio comprising 10 patent families, including US granted patents
- Extensive key organizational knowledge, including lab book data and R&D documentation
- Goodwill rights in the SeligoTM product brand
- Goodwill rights in the Apta Biosciences corporate brand
The successful purchaser was also given the opportunity to negotiate access to study data and consultancy of the inventors of the Company’s technology.
Highlight of this IP Sale
We identified a qualified buyer and successfully sold Apta’s highly specialized and uncommercialized technology. This technology had attracted more than $10m of investment and the Company had undertaken a successful R&D study with the National University of Singapore, using Seligo to target West Nile Virus and Dengue 2. This sale ensured this critical IP portfolio and the years of R&D investment was not lost as a result of a failed commercial venture.